The absence of PTEN protein expression is an independent prognostic marker in early stage resected lung adenocarcinoma. Inhibition of the PI3K/AKT/mTOR signal pathway can be an effective strategy to NSCLC harboring the EGFR activating mutations that acquires resistance to both TKIs and radiotherapy due...
尽管多款EGFR抗体和第三代EGFR受体酪氨酸激酶抑制剂(TKI)已经在肿瘤治疗中获得了广泛成功,但对于因耐药而导致的标准治疗失败或治疗后复发的肿瘤患者,仍存在未满足的临床需求。靶向EGFR的ADC药物有望克服这一耐药机制,为更多晚期肿瘤患...
Many patients developed into advanced stage of the disease when first diagnosed. With the discovery of epidermal growth factor receptor (EGFR) mutation in lung cancer, targeted therapy become an impor⁃ tant strategy for advanced NSCLC. It significantly prolonged the patients' survival. Although ...
Like @LesLavandes I have just found out through a series of blood tests (i had swollen lymph glands and also asked for an NHS health check) that I've been designated as CKD stage 3 and no-one told me previously. I have ulcerative colitis and so I have regular blood tests - my creat...
[50]. The two resulting fractions per sample, containing either unphosphorylated or phosphorylated peptides, were desalted by StageTips [49]. Prior to LC–MS/MS analysis the dry peptides were resolved in 50 mM citric acid and 0.1% TFA. LC–MS/MS analysis was performed using the mass ...
and the University of Chicago; many of these samples have appeared in previous publications [71–74], and 117 are new to this study (see Additional file5). The patients were heterogeneously treated in accordance with the standard of care dictated by their disease stage, ER, and HER2 status....
Current and future molecular testing in NSCLC, what can we expect from new sequencing technologies? J Clin Med. 2018;7(6). https://doi.org/10.3390/jcm7060144. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small-cell lung ...
genotyping of tumor tissue (either primary tumor or metastasis) in all patients with metastatic colorectal can- cer at the time of diagnosis of stage IV disease. The recom- mendation for KRAS testing at this point is not meant to indicate a preference regarding regimen selection in the first-...
49 L. Paz-Ares, J. Mezger, T.E. Ciuleanu, J.R. Fischer, J. von Pawel, M. Provencio, A. Kazarnowicz, G. Losonczy, G. de Castro, A. Szczesna, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung can...
testing, finding the original tissue block and reporting the test results is cumbersome, time-consuming, and prone to errors. Therefore, routine mutation testing at the time of initial diagnosis of stage II and III tumors should be considered. There is also a lack of validated testing methods ...